New mRNA vaccine targets brain infection in global trial
NCT ID NCT06680128
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests two new mRNA vaccines (GBP560) against Japanese encephalitis, a virus that can cause brain swelling. About 402 healthy adults will receive different doses of the vaccine or a comparison vaccine. Researchers will monitor safety and measure immune responses to find the best dose.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- mRNA vaccine (GBP560) against Japanese encephalitis
- What this could lead to
- If successful, this could lead to a new, more effective mRNA-based vaccine to prevent Japanese encephalitis, a serious brain infection.
- What could go wrong
- This is an early-phase trial (Phase 1/2) with only 402 participants. The vaccine may not produce a strong enough immune response or could have unexpected side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for JAPANESE ENCEPHALITIS VIRUS DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
New Zealand Clinical Research
NOT_YET_RECRUITINGChristchurch, Central City, 8011, New Zealand
-
Nucleus Network - Brisbane (Q Pharm)
RECRUITINGBrisbane, Australia
-
Nucleus Network - Melbourne
RECRUITINGMelbourne, Australia